UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $92.91 and traded as low as $77.62. UCB shares last traded at $79.88, with a volume of 104,130 shares traded.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average price is $92.17 and its two-hundred day moving average price is $94.67.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- EV Stocks and How to Profit from Them
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- What Are Growth Stocks and Investing in Them
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
